Coverage
-
February 28, 2019
AbbVie Inc. has agreed not to enter settlements that illegally delay the entry of certain generic drugs, allowing it to avoid a related trial over its testosterone treatment AndroGel slated to start Monday and officially putting an end to the landmark Federal Trade Commission v. Actavis litigation, the agency said Thursday.
26 other articles on this case.
View all »